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July 14, 2009:278–80reatinine method from Jaffe to enzymatic assays was not ac-
ounted for. Doubling of serum creatinine in major renal outcome
rials are confirmed by a second measurement of serum creatinine,
sually a month later than the first abnormal value (3,4). No such
onfirmatory measurements were carried out in the ONTARGET
tudy. Single central measures of urinary albumin/creatinine ratio
ere carried out at baseline, at 2 years, and at the end of the study.
epeated determinations are generally applied in renal outcome
rials due to huge variation in this ratio. The ONTARGET study
as not powered to detect differences in renal outcomes.
The primary renal outcome was driven by death (approximately
4% of all the events). A secondary renal outcome: any dialysis or
oubling of serum creatinine was similar with telmisartan (n 
89) and ramipril (n  174), and more frequent with combination
herapy (n  212, p  0.038 vs. ramipril, but p  NS vs.
elmisartan). In 3 of 165 originally reported cases of dialysis (5),
ater information revealed that no dialysis took place. In 3
dditional cases, no information could be obtained regarding
cute (2 months) or chronic dialysis (2 months) (n  61
38.4%] dealt with acute dialysis for various reasons but not for
yperkalemia). Removing acute dialysis from the renal end
oint led to insignificant differences between the 3 groups.
reatment trials in chronic kidney disease never include acute
ialysis in their primary end point (3,4,6,7). The number of
atients in chronic dialysis was very low (0.36% to 0.40%) and
early identical in the 3 arms.
The initial eGFR decline from baseline to 6 weeks was, as
xpected, significantly bigger during dual RAS blockade. This
nitial reversible hemodynamic phenomenon is well known, and
ainly due to lowering of glomerular capillary hydraulic pressure
8,9). The sustained decline in eGFR (ml/min/year) from 6 weeks
o final was 0.27 (ramipril), 0.44 (telmisartan), and 0.53 (com-
ined) (p  0.0001). These sustained reductions in eGFR are less
han normally expected due to aging (0.6 to 1.1 ml/min/year).
All groups had a rise from baseline to final in albumin/
reatinine ratio: 31% (ramipril), 24% (telmisartan), and 21%
combined). These findings are very surprising since previous
tudies dealing with angiotensin-converting enzyme inhibitors or
ngiotensin receptor blockers in kidney disease nearly always
howed a reduction (10).
The ONTARGET study, investigating RAS blockade in a
opulation with low risk for progressive kidney disease, applying
nsufficiently measured renal end points, confounded by death and
cute dialysis, has resulted in inconclusive evidence and misinter-
retation of the role of dual RAS blockade and importance of
lbuminuria as a valid surrogate end point for renal disease.
e echo the final statement in the Lancet editorial on the
NTARGET study: “A properly done prospective trial in patients
ith advanced proteinuric chronic kidney disease is still needed to
nswer definitively the question about efficacy of combination
herapy to block the RAS on progression of chronic kidney
rogression” (11). The proposed designed study is ongoing: the
LTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardio-
enal Endpoints) study (12).
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eply
n writing a viewpoint article on dual renin-angiotensin system
RAS) blockade (1), I seem to have inadvertently stepped into a
ornet’s nest. The ONTARGET (Ongoing Telmisartan Alone
nd in Combination with Ramipril Global Endpoint Trial) trial,
ike all studies, can be criticized, and in retrospect there is always
should’ve, would’ve, could’ve.” This is particularly true when
ndings go against the grain of what is perceived as a major
aradigm, namely, albuminuria/proteinuria being synonymous
ith renal outcome. Clearly, this paradigm was shattered by the
NTARGET study: in patients with relatively low urinary albu-
in excretion, dual RAS blockade compared with ramipril alone
as associated with a decrement in glomerular filtration rate
espite less progression in albuminuria. Thus, urinary albumin
xcretion can no longer be taken as a sign of renal outcome.
imilarly, preventing microalbuminuria or the transition from
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July 14, 2009:278–80icroalbuminuria to macroalbuminuria can no longer be taken as
foolproof sign of renal protection.
Dr. Parving and colleagues are puzzled about the rise from
aseline to final albumin/creatinine ratio in all 3 arms. They may
ave overlooked similar findings in the Micro-HOPE (Micro-
eart Outcomes Prevention Evaluation) study (2) and, of partic-
lar interest, in their own AVOID study (3) in the losartan arm.
ince many participants were on a RAS blocker before entering the
rial, an increase in urinary albumin excretion with time is not
nexpected.
Most patients with renal disease die of cardiovascular events
efore they ever reach dialysis. The ONTARGET study has
roven that dual RAS blockade as opposed to monotherapy with
n angiotensin-converting enzyme (ACE) inhibitor has no cardio-
ascular advantage. All renal trials done so far (including by some
f the authors of this letter to the editor) were underpowered to
ssess the effects of treatment on cardiovascular outcomes.
Dr. Parving and colleagues may also want to remember that in
he ONTARGET study the maximal dose of an ACE inhibitor
nd an angiotensin-receptor blocker (ARB) were tested. With a
ombination of submaximal doses as was done in many other
tudies, not surprisingly, a greater effect will be achieved with a
ombination than with monotherapy.
The importance of the dose is acknowledged by McMurray (4)
ho stated in the accompanying editorial of the ONTARGET
tudy, “The addition of an ARB to an ACE inhibitor has no
enefit. . .in patients with arterial disease but seems to be beneficial
n patients with heart failure, although the trials in heart failure did
ot test the addition of an ARB to a full dose of a proven ACE
nhibitor.” Could it be that indeed safety was the reason for not
esting full doses in heart failure?
Dr. McMurray and colleagues may also want to consider that a
ortality reduction of 11% (p  0.086) in heart failure was only
een in the CHARM/added (Candesartan in Heart Failure–
dded Trial) study and not in the ValHeft (Valsartan Heart
ailure Trial) study or the CHARM/alternative (Candesartan in
eart Failure–Alternative Trial) study. Of note, the bulk of benefit
n the ValHeft study occurred in a small group of patients who
ere ACE-inhibitor intolerant (and therefore only received
alsartan and not dual RAS blockade). The dose issue notwith-
tanding, this would indicate that the benefits of dual RAS
lockade in heart failure are not as ironclad as the authors would
ike us to think.
However, the CHARM study allows us to clearly identify aafety issue. Hyperkalemia was almost 5 times more common, andlevated creatinine occurred twice as much with dual RAS block-
de than with monotherapy. Since close monitoring is mandatory
n these patients, would it not it be more appropriate to add an
ldosterone blocker as the next step in heart failure rather than an
RB? Mortality was reduced by 25% (p  0.00001) with the
ddition of aldosterone blockade (5) as opposed to none of
ignificance with dual RAS blockade (6). Thus, the data in
ggregate (and cost) seem to favor aldosterone blockade over
RBs. Instead of fiddling around with dual and even triple RAS
lockade, physicians and patients would be much better served by
prospective randomized controlled trial serving to identify this
ext step in heart failure patients on ACE inhibitors.
As to guidelines, we should remember that converting data into
ecommendations requires invariably subjective judgments. Inher-
nt biases of the panel members may mold those judgments. Such
olding becomes of particular concern when panel members are
lso principle authors of studies that provide the data to be
onverted into guideline recommendations.
Franz H. Messerli, MD
St. Lukes-Roosevelt Hospital Center
ardiology
000 Tenth Avenue, Suite 3B-30
ew York, New York 10019
-mail: fmesserli@chpnet.org
doi:10.1016/j.jacc.2009.03.053
EFERENCES
. Messerli FH. The sudden demise of dual renin-angiotensin system
blockade or the soft science of the surrogate end point. J Am Coll
Cardiol 2009;53:468–70.
. Heart Outcomes Prevention Evaluation Study Investigators. Effects of
ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE
substudy. Lancet 2000;355:253–9.
. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, for the
AVOID Study Investigators. Aliskiren combined with losartan in type
2 diabetes and nephropathy. N Engl J Med 2008;358:2433–46.
. McMurray JJ. ACE inhibitors in cardiovascular disease—unbeatable?
N Engl J Med 2008;358:1615–6.
. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular
dysfunction: a systematic review of randomized clinical trials. Eur
Heart J 2009;30:469–77.
. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD,
Weingarten SR. Meta-analysis: angiotensin-receptor blockers in
chronic heart failure and high-risk acute myocardial infarction. Ann
Intern Med 2004;141:693–704.
